The verification layer between scientific claim and capital allocation.
The logic of scientific inquiry. The architecture of modern ML. The certainty of cryptographic proof.
Zetesis is a managed due-diligence service built on proprietary ML infrastructure. Every engagement is validated by the domain experts who built the system. Every verdict ships with a zero-knowledge cryptographic attestation: verifiable by any third party and tamper-evident by construction.
Claims fail at discipline boundaries: statistically credible but clinically incoherent, biologically plausible but regulatorily untenable. Zetesis runs a pre-registered battery across each boundary.
Causal inference, effect-size plausibility, population structure.
Multiple-testing burden, model assumptions, replication.
Endpoint validity, patient-population fit, translation path.
Target engagement, PK/PD, mechanism coherence.
FDA/EMA precedent, trial-design feasibility, approval-path risk.
Claim defensibility, freedom-to-operate, competitive encirclement.
The ML runs the investigation. The domain experts who built the system validate the verdict before release. The output is an audit-grade report delivered inside deal-timeline windows.
A layered architecture. Every verdict traverses each layer, in order.
The evolving scientific corpus every layer above reasons over.
Continuously trained. Accuracy compounds as the record evolves.
Domain-specialized agents, coordinated in parallel.
The protocol locks before execution. Reproducibility by construction.
Independently verifiable. Tamper-evident by design.
Omics-derived therapeutic platforms are now the dominant source of biotech deal flow. The claims that underpin them are themselves computational: gene–disease association scores, ML-generated target predictions, pattern-library matches in multi-omics datasets. Zetesis exists to verify these at investment grade.
Omics is the first domain. The verification architecture extends to any scientific claim that can be audited against the live research record. Genomics today; materials, chemistry, and physics next.
Ophthalmology resident at Rambam Health Care Campus and MSc candidate in Computational Medicine at the Rappaport Faculty of Medicine, Technion. Research focus: multi-omics approaches to ocular disease, including epigenetic ocular longevity, oncology pharmacogenomics, and drug-target discovery.
Assistant Professor, Rappaport Faculty of Medicine, Technion. Information processing in biological systems; ML for drug discovery, digital pathology, biomedical signal interpretation. BSc Technion (Physics + EE); MSc/PhD Weizmann Institute; postdoc Harvard Medical School.
Zetesis is accepting charter clients from healthcare-focused venture firms, corporate venture arms, family offices, and deep-tech funds. Bring a live claim; we'll run the assessment.
Request a charter engagement →